Nick Mourlas

🚀 Gen AI is revolutionizing the life sciences industry, unlocking immense potential for personalized medicine, drug discovery, and diagnostics. Here are 5️⃣ 🔑 points from my wonderful colleagues Lisa Arbogast and Harini Gopalakrishnan and their new blog post: 1️⃣ From genome sequencing to drug development, AI has transformed life sciences, saving time and costs. 2️⃣ Gen AI is predicted to create $60-110B in annual economic value for pharmaceutical and medtech companies by 2031. 3️⃣ Challenges include security concerns, data privacy regulations, and implementing AI solutions in existing workflows. 4️⃣ Gen AI offers benefits like accelerated research, optimized manufacturing, and enhanced commercialization. 5️⃣ Companies must decide between building a custom solution or purchasing a pre-built one, considering factors like budget, expertise, and specific needs. With Snowflake's AI Data Cloud platform and tools, life sciences companies can develop a strong data foundation for GenAI, enabling meaningful innovation to improve patient outcomes. Who's ready?! #GenAI #LifeSciences #PersonalizedMedicine #DrugDiscovery #Diagnostics #snowflake #pharma #healthdata #healthtech #LLM #research #development Blog: https://lnkd.in/ezfb9H_z

8

1 Comment

📢 It's that time again Friday's Innov8Search Insights! If you would like the links to the full articles comment below or DM me). 🚨Bain Capital Life Sciences Fund LP raises a $1.9B fund to back biopharma, med devices, diagnostics, and digital health innovations worldwide, from early to late-stage opportunities. 🚀 #HealthcareInnovation #LifeSciences #VentureCapital 🚨FDA approves Apple’s OTC hearing aid software, signaling a major step in integrating consumer tech with healthcare. New sleep health applications are also under review, expanding access to health support. #HealthInnovation #RegulatoryNews #DigitalHealth #WearableTech 🚨 Medtech VC investment rises 3% to $3.3B in Q2 2024, but startup M&A remains rare due to price gaps, per PitchBook. Notable: INSIGHTEC's $150M round. Will the IPO window open wider? #MedTech #VentureCapital #StartupInvestment #HealthcareInnovation 🚨 Abbott integrates Freestyle Libre 3 Plus CGM with Beta Bionics' iLet Bionic Pancreas, aiming to automate insulin delivery. Launch set for Q4 as Abbott expands in the AID market. #DiabetesCare #MedTech #GlucoseMonitoring #Innovation 🚨 Solventum, spun off from 3M, unveils its VAC Peel and Place Dressing, designed to simplify negative pressure wound therapy and reduce dressing changes. #MedTech #HealthcareProfessionals #WoundCareInnovation 🚨 Neuspera Medical Inc. Medical appoints Bunty Banerjee as COO to lead R&D and operations as the company advances its neuromodulation system for overactive bladder, post $23M Series D funding. #MedTech #Neuromodulation #Leadership #LifeSciences 🚨 Medtronic names Dr. James Porter as Chief Medical Officer for its Robotic Surgical Technologies and Digital Technologies unit to drive innovation and strategy. #MedTech #RoboticSurgery #DigitalHealth #Leadership 🚨Getinge finalizes its $477M deal to acquire Paragonix Technologies, Inc., enhancing its organ transplant tech portfolio and driving new innovations. #MedTech #OrganTransplant #HealthcareInnovation 🚨Eli Lilly and Company strikes a $1B deal with HAYA Therapeutics to develop long non-coding RNA (lncRNA) therapies for obesity and metabolic diseases, aiming to be "first in biology" with this emerging technology. #Biotech #Pharma #GeneTherapy #Innovation #MetabolicHealth 🚨New biotech Candid Therapeutics, led by veterans from RayzeBio, has secured $370M to develop T cell engagers for inflammatory conditions. The company plans to start clinical trials next year, betting on bispecific antibodies as a promising approach for autoimmune diseases. #Biotech #AutoimmuneDisease #Innovation #Therapeutics

34

3 Comments

Congratulations to Alex, Lindsay, Michelle, and the rest of the Talus Bio team on the latest financing! This will be transformative for the team as they work to develop new drugs to target transcription factors. 👩‍🔬 What does the company do? Talus uses their platform to test for the effect of novel TF-targeted drugs in a live cell opening up the possibility of drugging many previously 'undruggable' targets. 💊 What do they have so far? The company is working on four targets including #brachyury for treating a rare cancer called #chordoma. 💸 Who is investing? The round is led by a stellar team at Two Bear Capital (J. Seth Strattan PhD and Avery Sonnenberg), with participation from Washington Research Foundation, BoxOne Ventures, and NFX 🌎 Why does this matter? Talus has an impressive technology that hopefully can create new treatment options for some serious conditions. The team worked doggedly to build the company off of grants in a harsh market cycle and this investment validates how far they've come. I'm excited to have this team in Seattle helping build the next generation of great biotech companies here! #biotech #financing #company #seattle

78

1 Comment

We were thrilled today to be part of NVIDIA Healthcare's presentation, given by their head of Healthcare, Kimberly Powell, at the 2024 HLTH Inc. Conference MainStage session. Over the past months, ConcertAI and NVIDIA AI have collaboratively advanced a multi-LLM NIMs-based and Agentic AI architecture, as part of ConcertAI’s CARAai Platform, powering Oncology Clinical Development Suite from study design to patient-to-trial matching. This solution can be deployed in any major cloud. The CARAai workflows replace legacy OCR, NLP and AI and offers exceptionally low latency, precision and recall approaching expert human performance when reading EMR notes and documents -- all assuring a broader population of patients, across all settings of care, can be considered for potential life-saving clinical trials. Our thanks to, Kimberly Powell, Brad Genereaux, Kyle Hatley, Rory Kelleher, Vega Shah, PhD Jesse Tetreault Stephen Yip, PhD Ryan Kennedy #ConcertAI #NVIDIA #AI #precisiononcology #oncologytrials #AIforGood

235

12 Comments

Investment, therapeutic viability, and next-gen. technologies... That's what the cell therapy field needs. I had the pleasure of sitting down with Jason C. Foster of Ori Biotech recently on their podcast to talk all things cell therapy, the enabling technologies that support this modality, and the need for more investment. What did we touch on (and link to full podcast below)? Investors needing to see a return when investing in cell therapies. Need to bring manufacturing costs down to expand access. Next-gen. tools to create better, more robust therapies. Purpose-built therapies require purpose-built tools! Our consulting practice, how we help our clients, and how we view the field of advanced therapies. We take a differentiated approach to tracking, following, and mapping key trends across advanced therapies to bring novel, business-impacting insights to our clients. Want to discuss any of the above? Where the field of cell therapies are going? What it means for your own development pipeline? Reach out and let me know what you think in the comments! #celltherapy #venturecapital #consulting https://lnkd.in/g7SH9FAU

51

3 Comments

$37,000 per day. That's the cost of delayed MedTech development. No wonder companies are looking beyond U.S. borders. Latin America offers a solution: • Faster regulatory approval • Lower costs (50-70% savings reported) • Quality data accepted by FDA I've seen startups thrive here, especially in Colombia. Key to success? • Local CRO with MedTech focus • Experienced PI who's genuinely interested • Flexible research sites Remember: It's about smart globalization, not cutting corners. Have you considered OUS trials? What's holding you back? #MedicalDevices #ClinicalResearch #bioaccess

4